Veracyte, Inc.
A maker of genomic tests that help doctors decide how to treat cancer, Veracyte reads a patient's tumor biology to answer questions like whether a thyroid nodule is benign or a prostate cancer needs aggressive treatment. Its best-known products are the Afirma thyroid test and the Decipher prostate test. Founded in 2006 as Calderome and renamed in 2008, the company's name blends the Latin for "truth" with the Greek suffix for "cell" — a nod to revealing what a patient's cells actually say.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| FMR LLC | 13G/APassive | 10.1% | 8.06M | Jun 5, 2026 |
| Abigail P. Johnson | 13G/APassive | 10.1% | 8.06M | Jun 5, 2026 |
| Artisan Partners Asset Management Inc. | 13G/APassive | 6.9% | 5.50M | May 13, 2026 |
| Artisan Partners Holdings LP | 13G/APassive | 6.9% | 5.50M | May 13, 2026 |
| Artisan Investments GP LLC | 13G/APassive | 6.9% | 5.50M | May 13, 2026 |
| Artisan Partners Limited Partnership | 13G/APassive | 6.9% | 5.50M | May 13, 2026 |
| STATE STREET CORPORATION | 13GPassive | 6.3% | 5.04M | May 12, 2026 |
| Vanguard Capital Management | 13GPassive | 5.2% | 4.13M | Apr 30, 2026 |
| Vanguard Portfolio Management | 13GPassive | 5.67% | 4.51M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 27, 2026 |